Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Anatomic Changes in Schlemm's Canal and Collector Channels in Normal and Primary Open-Angle Glaucoma Eyes Using Low and High Perfusion Pressures
Hann, Cheryl R., Vercnocke, Andrew J. , Bentley, Michael D., Jorgensen, Steven M., Fautsch, Michael P.

Investigative Opthalmology & Visual Science | August 20, 2014 | Volume: 55 | Issue: 9 | Pages: 5834

10.1167/iovs.14-14128 | PMID 25139736 Get It

Coronary Artery Tortuosity in Spontaneous Coronary Artery Dissection
Eleid, Mackram F. , Best, Patricia J.M. , Vrtiska, Terri J., Prasad, Megha , Rihal, Charanjit S. , Gulati, Rajiv , Guddeti, Raviteja R, Tweet, Marysia S. , Best, Patricia J., Guddeti, Raviteja , Lerman, Amir , Singh, Mandeep , Rihal, Charanjit S. , Hayes, Sharonne N.

Circulation: Cardiovascular Interventions | August 20, 2014 | Volume: 7 | Issue: 5 | Pages: 656-662

10.1161/circinterventions.114.001676 | PMID 25138034 Get It

Background— Spontaneous coronary artery dissection (SCAD) is an increasingly recognized nonatherosclerotic cause of acute coronary syndrome. The angiographic characteristics of SCAD are largely undetermined. The goal of this study was to determine the prevalence of coronary tortuosity in SCAD and whether it may be implicated in the disease. Methods and Results— Patients with confirmed SCAD (n=246; 45.3±8.9 years; 96% women) and 313 control patients without SCAD or coronary artery disease who underwent coronary angiography were included in this case–control study. Angiograms were reviewed for coronary tortuosity and assigned a tortuosity score. Tortuosity was common in patients presenting with their first SCAD event (78% versus 17% in controls; P <0.0001; tortuosity score, 4.41±1.73 versus 2.33±1.49 in controls; P <0.0001) despite a low prevalence of hypertension (34%). Recurrent SCAD (n=40) occurred within segments of tortuosity in 80% of cases. Severe tortuosity (≥2 consecutive curvatures ≥180°) was associated with a higher risk of recurrent SCAD (hazard ratio, 3.29; 95% confidence interval, 0.99–8.29; P =0.05). Tortuosity score >5 was associated with a trend toward higher risk of recurrent SCAD ( P =0.16). Prespecified angiographic markers of tortuosity including corkscrew appearance and multivessel symmetrical tortuosity were associated with extracoronary vasculopathy including fibromuscular dysplasia ( P <0.05 for both). Conclusions— Coronary artery tortuosity is highly prevalent in the SCAD population and is associated with recurrent SCAD. Recurrent SCAD most often occurs within segments of tortuosity. Angiographic features of SCAD are associated with extracoronary vasculopathy, including fibromuscular dysplasia. These findings suggest that coronary tortuosity may serve as a marker or potential mechanism for SCAD.
Tadalafil for Erectile Dysfunction Prevention After Radiotherapy for Prostate Cancer—Reply
Pisansky, Thomas M. , Bruner, Deborah Watkins , Greenberg, Richard E. , Bruner, Deborah

JAMA | August 19, 2014 | Volume: 312 | Issue: 7 | Pages: 748

10.1001/jama.2014.7923 | PMID 25138339 Get It

Electroporation
Asirvatham, Samuel J. , Kapa, Suraj , DeSimone, Christopher V. , Asirvatham, Samuel J

Circulation: Arrhythmia and Electrophysiology | August 19, 2014 | Volume: 7 | Issue: 4 | Pages: 573-575

10.1161/circep.114.001999 | PMID 25140018 Get It

Editor’s Perspective: Electrocardiogram Mapping–Reentry
Asirvatham, Samuel J. , Stevenson, William G. , Asirvatham, Samuel J

Circulation: Arrhythmia and Electrophysiology | August 19, 2014 | Volume: 7 | Issue: 4 | Pages: 760-761

10.1161/circep.114.001928 | PMID 25140022 Get It

Newborn Screening for Severe Combined Immunodeficiency in 11 Screening Programs in the United States
Kwan, Antonia , Abraham, Roshini S. , Currier, Robert J. , Andruszewski, Karen, Abbott, Jordan K. , Ballow, Mark, Bartoshesky, Louis, Bonilla, Francisco A., Brokopp, Charles D., Brooks, Edward G. , Caggana, Michele, Celestin, Jocelyn, Church, Joseph A., Comeau, Anne Marie , Connelly, James A. , Cowan, Morton J. , Cunningham‐Rundles, Charlotte , Dasu, Trivikram , Dave, Nina, Morena, M. Teresa de la , Duffner, Ulrich, Fong, Chin-To, Forbes, Lisa R., Freedenberg, Debra, Gelfand, Erwin W. , Hale, Jaime E. , Hanson, I. Celine , Hay, Beverly N., Hu, Diana, Infante, Anthony J., Johnson, Daisy, Kapoor, Neena , Kay, Denise M. , Lee, Rachel , Lehman, Heather K. , Lin, Zhili, Lorey, Fred, Abdel‐Mageed, Aly, Manning, Adrienne, McGhee, Sean, Naides, Stanley J. , Orange, Jordan S. , Pai, Sung‐Yun , Porteus, Matthew H. , Rodríguez, Ray, Romberg, Neil , Routes, John M. , Ruehle, Mary, Rubenstein, Arye, Saavedra‐Matiz, Carlos A., Scott, G. E. M., Scott, Patricia M., Secord, Elizabeth , Seroogy, Christine M. , Shearer, William T. , Siegel, Subhadra , Silvers, Stacy K., Stiehm, E. Richard, Sugerman, Robert W., Sullivan, John L., Tanksley, Susan, Tierce, Millard L., Verbsky, James , Vogel, Beth , Walker, Rosalyn, Walkovich, Kelly, Walter, Jolán E. , Watson, Michael S., Weinberg, Geoffrey A. , Weiner, Leonard B. , Wood, Heather, Yates, Anne, Puck, Jennifer M. , Satter, Lisa Forbes , Brower, Amy , Baker, Mei Wang , Kohn, Donald B. , Moore, Theodore Bruce , Notarangelo, Luigi D , Walker, Rosalyn, Wasserman, Richard L. , Currier, Robert , Forbes Satter, Lisa R

JAMA | August 19, 2014 | Volume: 312 | Issue: 7 | Pages: 729

10.1001/jama.2014.9132 | PMID 25138334 Get It

A Phase IB multicentre dose‐determination study of BHQ880 in combination with anti‐myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal‐related events
Iyer, Swaminathan P. , Beck, Joseph Taddeus, Stewart, A. Keith, Shah, Jatin J., Kelly, Kevin R. , Isaacs, Randi , Bilic, Sanela , Munshi, Nikhil C. , Sen, Suman

British Journal of Haematology | August 19, 2014 | Volume: 167 | Issue: 3 | Pages: 366-375

10.1111/bjh.13056 | PMID 25139740 Get It

SummaryDickkopf‐1 (DKK1), expressed by myeloma cells, suppresses osteoblast function and plays a key role in bone disease in multiple myeloma. BHQ880, a human neutralizing IgG1 anti‐DKK1 monoclonal antibody, is being investigated for its impact on multiple myeloma‐related bone disease and as an agent with potential anti‐myeloma activity. The primary objectives of this Phase IB study were to determine the maximum tolerated dose (MTD) of BHQ880 and to characterize the dose‐limiting toxicity (DLT) of escalating doses in combination with anti‐myeloma therapy and zoledronic acid. Twenty‐eight patients were enrolled and received BHQ880 at doses of 3–40 mg/kg. No DLTs were reported, therefore, the MTD was not determined. The recommended Phase II dose was declared as 10 mg/kg, based mainly on saturation data. There was a general trend towards increased bone mineral density (BMD) observed over time; specific increases in spine BMD from Cycle 12 onwards irrespective of new skeletal‐related events on study were observed, and increases in bone strength at the spine and hip were also demonstrated in some patients. BHQ880 in combination with zoledronic acid and anti‐myeloma therapy was well tolerated and demonstrated potential clinical activity in patients with relapsed or refractory multiple myeloma.
Is the incidence of malignancy increased in patients with sarcoidosis? A systematic review and meta‐analysis
Ungprasert, Patompong , Srivali, Narat , Wijarnpreecha, Karn , Cheungpasitporn, Wisit , Knight, Eric L., Thongprayoon, Charat , Cheungpasitporn, Wisit , Srivali, Narat , Wijarnpreecha, Karn

Respirology | August 19, 2014 | Volume: 19 | Issue: 7 | Pages: 993-998

10.1111/resp.12369 | PMID 25138430 Get It

AbstractA possible causal relationship between sarcoidosis and malignancy has been the subject of debates for decades. To better understand this association, we conducted a systematic review and meta‐analysis of cohort studies that reported relative risk, hazard ratio or standardized incidence ratio with 95% confidence interval (CI) comparing the incidence of malignancy in patients with sarcoidosis versus non‐sarcoidosis participants. Pooled risk ratios (RR) and 95% CI were calculated using a random‐effect, generic inverse variance methodology. Five studies were identified and included in our data analyses. The pooled RR of malignancy in patients with sarcoidosis was 1.21 (95% CI: 1.04–1.40). However, when we performed a sensitivity analysis that included only studies that compared the incidence of malignancy after the first year of the diagnosis of sarcoidosis with the incidence of malignancy after the first year of index date for non‐sarcoidosis controls, the pooled risk ratio decreased and did not reach statistical significance (RR 1.13, 95% CI: 0.97–1.32). Furthermore, analysis for publication bias has suggested that publication bias in favour of positive studies may be present. In conclusion, after accounting for possible detection bias and publication bias, there does not appear be a significant association between sarcoidosis and malignancy.
Republished: Clinical implications of the Third Universal Definition of Myocardial Infarction
Thygesen, Kristian , Alpert, Joseph S., Jaffe, Allan S. , White, Harvey Douglas , Jaffe, Allan S.

Postgraduate Medical Journal | August 19, 2014 | Volume: 90 | Issue: 1067 | Pages: 502-510

10.1136/postgradmedj-2012-302976rep | PMID 25140007 Get It

Reply to C.D. Atkins and A. Avan et al
Loprinzi, Charles L. , Qin, Rui , Grothey, Axel

Journal of Clinical Oncology | August 19, 2014 | Volume: 32 | Issue: 29 | Pages: 3342-3343

10.1200/jco.2014.57.2537 | PMID 25135995 Get It